MODIFICATION
66 -- Detection Reagents
- Notice Date
- 6/23/2015
- Notice Type
- Modification/Amendment
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIDA-SSSA-NOI-15-224
- Archive Date
- 7/17/2015
- Point of Contact
- Andrea McGee, Phone: 3014358781
- E-Mail Address
-
amcgee@nida.nih.gov
(amcgee@nida.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- SOLICITATION NUMBER: HHS-NIH-NIDA-SSSA-NOI-15-224 TITLE: Detection Reagents INTRODUCTION This is a pre-solicitation non-competitive (notice of intent) synopsis to award a contract without providing for full or open competition (including brand-name). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSAL. A SOLICITATION WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Institute on Drug Abuse (NIDA), Consolidated Station Support and Simplified Acquisitions (CSS/SA) Branch intends to negotiate and award a purchase order to Promega Corporation for detection reagents. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 325414 with a size standard of 500 employees. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the through Federal Acquisition Circular (FAC) 2005-82 effective May 7, 2015. This acquisition is for a commercial item or service and is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures. This acquisition is NOT expected to exceed the simplified acquisition threshold. STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1. DESCRIPTION OF REQUIREMENT Purpose and Objectives: The purpose of this requirement is to acquire the purchase of detection reagents from Promega Corporation: ONE-Glo TM Luciferase Assay System, CellTiter-Fluor TM Cell Viability Assay and CellTiter-Glo ® Cell Viability Assay. Project Background: The Tox21 group of National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation (DPI) will screen compounds from Tox21 10K library with an assays like CAR (two modes: agonist and antagonist), SHH Gli3 (two modes) etc. which are some of current ongoing projects for a luciferase based methods. All the luciferase based methods are multiplexed with a cytotoxicity assay by using CellTiter-Fluor TM Cell Viability Assay. The ONE-Glo TM Luciferase Assay System is required for detection of luciferase based assays and the other two assay systems are required to run a parallel Cytotoxicity assays to each and every approved Tox21 assays. All these cells contain a luciferase reporter gene (Luc) under the control of a target (gene) response element and the detection of stimulation or inhibition of the target genes is by measuring the firefly luciferase reporter gene expression in cells in terms of relative luminescence units. For the hCAR assay, luciferase activity is detected in a double-stable hCAR1-CYP2B6-HepG2 cell line. HepG2 cells were transfected with a pEF6/V5- hCAR1 expression plasmid and a pGL4.17[luc2/Neo]-CYP2B6-2.2kb construct containing both the PBREM and XREM. For AR_MDA, Luciferase activity is detected in stable transformed MDA- MB-453 cells, with MMTV.luciferase.neo reporter gene construct. For CMV-Luc, Luciferase activity is detected by measuring luciferse 2 reporter gene expression in stable transformed Hek293 cells with CMV promoter. So, all these screenings (hCAR, AR-MDA and CMV-Luc) require ONE-Glo TM Luciferase assay system and CellTiter-Fluor TM Cell Viability assay systems. ONE-Glo TM Luciferase assay system detects the expression of luciferase reporter gene, whereas CellTiter-Fluor TM Cell Viability assay systems is used for measuring the relative number of viable cells based on measurement of protease activity within live cells. This assay system is always been used in conjunction (or by multiplexing) with the ONE-Glo assay. CellTiter-Glo® cell Viability assay is used for measuring the cytotoxicity of the projects which are mainly aimed to detect the toxicity of the Tox21 chemicals against the target of interest. But in most of the Tox21 assays, this reagent is also used in conjunction with the fluorescence based assays (such as HRE-bla ME-180) for measuring the number of viable cells in cells based on the quantitation of the ATP present. Project Requirements: E6130 ONE-Glo(TM) Luciferase Assay System, 1L Qty 20 G6082 CellTiter-Fluor(TM) Cell Viability Assay, 2 x 50ml Qty 50 G8462 CellTiter-Glo(R) One Solution Assay, 500ml Qty 20 This request (ONE-Glo and CellTiter-Fluor) will be used for screening against Tox21 compounds for the following cell lines: 1. hCAR (for two modes: agonist and antagonist mode) 2. AR-MDA (for one mode: antagonist mode) 3. CMV-Luc (for one mode: agonist mode) Anticipated period of performance: 1 to 3 days ARO. CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, PROMEGA CORPORATION is the only vendor in the current market place that can provide the unique services required by the of National Center for Advancing Translational Sciences. In accordance with FAR part 10, extensive market research was conducted to reach this determination. Specifically, a small business sources sought notice was posted to FedBizOpps referencing the above detailed requirements and no responses were received. Therefore, only PROMEGA CORPORATION is capable of meeting the needs of this requirement. The intended source is: Promega Corporation 2800 Woods Hollow Rd Mafison, WI 53711 CLOSING STATEMENT THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses shall be submitted no later than July 2, 2015 at 4:30pm EST. Responses may be submitted electronically to amcgee@nih.gov or by U.S. mail to the National Institute of Drug Abuse (NIDA), Station Support / Simplified Acquisition Branch (SS/SA), Attention: Andrea McGee. Fax responses will not be accepted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/HHS-NIH-NIDA-SSSA-NOI-15-224/listing.html)
- Place of Performance
- Address: 9800 Medical Center Drive, Rockville, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN03773602-W 20150625/150623235550-fdc450603eeb8722af57ddd7762be625 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |